Training Title: Ms Jess Davies, Female, 30 Years Old

Training Title 24name Ms Jess Daviesgender Femaleage 30 Years Oldt

Analyze the clinical presentation and behavioral symptoms of Ms. Jess Davies, a 30-year-old female with a history of depression, recent traumatic events, substance use, and psychotic-like symptoms. Evaluate her mental health condition, possible diagnoses, and appropriate treatment considerations based on her history, behaviors, and reported experiences.

Paper For Above instruction

Ms. Jess Davies presents a complex mental health case characterized by symptoms indicative of psychosis, mood disturbance, substance use, and trauma-related responses. Her clinical history, behavioral manifestations, and reported thoughts provide critical insights into her current mental state and potential diagnostic pathways.

Firstly, Ms. Davies exhibits features suggestive of psychosis, notably auditory hallucinations and paranoid ideations. She reports hearing voices that others do not hear, specifically associating these auditory experiences with Russian individuals and a perceived invasion of her thoughts by foreign entities. Her statements about being watched, the belief that her apartment walls contain blueprints of buildings, and her assertion of being able to "stop" others from viewing these blueprints, reflect paranoid delusions and perceptual distortions typical of psychotic episodes (American Psychiatric Association, 2013). Her description of hearing conversations when no one else is present and her assertion of knowledge unavailable to others further consolidates concerns of psychosis, perhaps schizophrenia-spectrum disorder or a severe form of delusional disorder (Kirk & Kircanski, 2021).

Secondly, her mood disturbances are evident. Although she exhibits depressive symptoms, such as social withdrawal, poor appetite, and disturbed sleep, these appear to be exacerbated by her trauma exposure, including witnessing her brother's murder and her strained family relationships. Her statements about witnessing traumatic violence and her current social isolation suggest post-traumatic stress responses (Cloitre et al., 2019). Her history of depression post-aunt's death, combined with her current presentation, indicates a probable comorbid mood disorder that influences her overall clinical picture.

Thirdly, substance use plays a significant role in her mental health dynamics. Ms. Davies admits to daily cannabis use since age 17 and occasional alcohol consumption. Cannabis, especially when used frequently, can exacerbate psychotic symptoms, particularly in individuals predisposed to psychosis (van der Poel et al., 2019). Her prescribed medication, alprazolam, suggests recent management for anxiety or agitation; however, her self-reported cessation of medications, claiming they contributed to her issues, raises concerns about untreated or undertreated psychiatric conditions and possible medication non-compliance, which can precipitate or worsen psychotic episodes (Singh et al., 2020).

Moreover, her presentation is complicated by trauma-related symptoms. Witnessing her brother's murder, experiencing estrangement from her parents, and expressing beliefs of being monitored and involved in covert governmental activities indicate significant trauma exposure with possible development of complex PTSD (Herman, 2015). Her statements about secret blueprints and perceived threats involving terrorists further suggest paranoid ideation fueled by trauma, stress, and substance use.

Assessment and diagnosis require comprehensive consideration. Differential diagnosis should include schizophrenia-spectrum disorders, schizoaffective disorder, bipolar disorder with psychotic features, or substance-induced psychosis. Given her history, an axis I diagnosis of schizophrenia or schizoaffective disorder may be appropriate, considering her persistent auditory hallucinations, paranoid delusions, and social withdrawal (Barch & Dowd, 2019). The influence of cannabis may have precipitated or contributed to the psychotic phenomena, a common occurrence in predisposed individuals (Di Forti et al., 2019). Her trauma history suggests that trauma-related residual symptoms or PTSD may coexist, complicating her symptoms and treatment needs.

In terms of treatment, an integrated approach addressing psychosis, trauma, and substance use is essential. Pharmacologically, antipsychotics such as risperidone or olanzapine could be effective in controlling hallucinations and delusions (Kane et al., 2020). Concurrently, addressing substance use through Motivational Interviewing and psychoeducation about cannabis's effects on psychosis is essential (Mudelsee et al., 2021). Trauma-focused therapies, including Cognitive Processing Therapy (CPT) or Eye Movement Desensitization and Reprocessing (EMDR), may assist in processing traumatic memories and reducing PTSD symptoms (Foa et al., 2018). Additionally, psychosocial interventions including psychoeducation, social skills training, and family involvement are crucial for functional recovery and relapse prevention.

Monitoring for suicidality and safety concerns is critical, as her social isolation and expressed paranoia pose ongoing risks. Establishing a supportive therapeutic relationship, ensuring medication compliance, and enhancing her social support structure are vital components of her treatment plan (Herman & McAlpine, 2019). Furthermore, attention to her substance use history is important, as ongoing cannabis use can impede recovery and exacerbate psychosis symptoms (Sevy et al., 2019).

In conclusion, Ms. Jess Davies’s presentation suggests a primary psychotic disorder with co-occurring trauma and substance use issues. An accurate diagnosis will depend on further assessment, including collateral information and mental status examination. A multidisciplinary treatment plan involving pharmacotherapy, psychotherapy, substance use intervention, and trauma therapy offers the best approach for her recovery. Given her complex psychosocial circumstances, ongoing support and monitoring are essential to improve her functioning and quality of life.

References

  • American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.).
  • Barch, D., & Dowd, E. (2019). Schizophrenia spectrum disorders: New insights. Annual Review of Clinical Psychology, 15, 371-394.
  • Cloitre, M., et al. (2019). Trauma and PTSD. Journal of Traumatic Stress, 32(5), 747-757.
  • Di Forti, M., et al. (2019). The role of cannabis in psychosis. Schizophrenia Bulletin, 45(4), 747-756.
  • Foa, E. B., et al. (2018). Cognitive Behavioral Therapy for PTSD. Guilford Publications.
  • Herman, J. L. (2015). Trauma and recovery: The aftermath of violence—from domestic abuse to political terror. Basic Books.
  • Herman, R., & McAlpine, D. (2019). Managing psychosis in young adults. Psychiatric Services, 70(3), 232-236.
  • Kane, J. M., et al. (2020). Risperidone for schizophrenia. New England Journal of Medicine, 382, 1521-1530.
  • Kirk, B., & Kircanski, K. (2021). Psychosis: Diagnostic challenges and treatment strategies. Psychiatric Clinics, 44(3), 365-382.
  • Mudelsee, A., et al. (2021). Cannabis use and psychosis risk: Prevention strategies. Addiction, 116(4), 857–866.
  • Sevy, S., et al. (2019). Substance use and first-episode psychosis. Schizophrenia Research, 206, 191–196.

Related Assignments